Tags

Type your tag names separated by a space and hit enter

Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers.
Pharmacogenet Genomics. 2007 Nov; 17(11):1001-5.PG

Abstract

INTRODUCTION

Cytochrome P450 1A2 (CYP 1A2) is responsible for more than 90% of caffeine clearance. A polymorphic variant of CYP1A2 (-163C>A) (rs762551) is associated with high CYP1A2 inducibility. Both caffeine and its main metabolite, paraxanthine, may be neuroprotective. The association between caffeine intake and risk of Parkinson's disease (PD) in fast and slow caffeine metabolizers has not been compared.

OBJECTIVE

In a case-control study, we analyzed the relationship between caffeine intake and risk of PD in both fast and slow caffeine metabolizers.

METHODS

All the study participants were recruited prospectively, and interviewed for information on the amount and duration of caffeine intake. Genotyping of the CYP1A2 variant was carried out using the allelic discrimination method.

RESULTS

Out of 1000 participants who were initially screened, 886 consisting of 418 PD and 468 race, sex and age matched controls were included. No evidence existed to suggest any association between CYP1A2 and the onset of PD (P=0.08). A significant association was seen between caffeine intake and the onset of PD (P=2.01x10(-5)), with the odds ratio for moderate and high drinkers at 0.71 [95% confidence interval (CI): 0.50-1.00] and 0.47 (95% CI: 0.34-0.65), respectively against the low drinkers. Multivariate analysis revealed no evidence of any interaction effects of caffeine with CYP1A2 (P=0.956).

CONCLUSION

The association between caffeine intake and risk of PD was similarly observed in both fast and slow caffeine metabolizers, supporting experimental evidence in animal models that both caffeine and its major metabolite, paraxanthine, are neuroprotective.

Authors+Show Affiliations

Departments of Neurology, Singapore General Hospital, Singapore. gnrtek@sgh.com.sgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18075470

Citation

Tan, Eng-King, et al. "Association Between Caffeine Intake and Risk of Parkinson's Disease Among Fast and Slow Metabolizers." Pharmacogenetics and Genomics, vol. 17, no. 11, 2007, pp. 1001-5.
Tan EK, Chua E, Fook-Chong SM, et al. Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenet Genomics. 2007;17(11):1001-5.
Tan, E. K., Chua, E., Fook-Chong, S. M., Teo, Y. Y., Yuen, Y., Tan, L., & Zhao, Y. (2007). Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenetics and Genomics, 17(11), 1001-5.
Tan EK, et al. Association Between Caffeine Intake and Risk of Parkinson's Disease Among Fast and Slow Metabolizers. Pharmacogenet Genomics. 2007;17(11):1001-5. PubMed PMID: 18075470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. AU - Tan,Eng-King, AU - Chua,Eva, AU - Fook-Chong,Stephanie M, AU - Teo,Yik-Ying, AU - Yuen,Yih, AU - Tan,Louis, AU - Zhao,Yi, PY - 2007/12/14/pubmed PY - 2008/1/16/medline PY - 2007/12/14/entrez SP - 1001 EP - 5 JF - Pharmacogenetics and genomics JO - Pharmacogenet Genomics VL - 17 IS - 11 N2 - INTRODUCTION: Cytochrome P450 1A2 (CYP 1A2) is responsible for more than 90% of caffeine clearance. A polymorphic variant of CYP1A2 (-163C>A) (rs762551) is associated with high CYP1A2 inducibility. Both caffeine and its main metabolite, paraxanthine, may be neuroprotective. The association between caffeine intake and risk of Parkinson's disease (PD) in fast and slow caffeine metabolizers has not been compared. OBJECTIVE: In a case-control study, we analyzed the relationship between caffeine intake and risk of PD in both fast and slow caffeine metabolizers. METHODS: All the study participants were recruited prospectively, and interviewed for information on the amount and duration of caffeine intake. Genotyping of the CYP1A2 variant was carried out using the allelic discrimination method. RESULTS: Out of 1000 participants who were initially screened, 886 consisting of 418 PD and 468 race, sex and age matched controls were included. No evidence existed to suggest any association between CYP1A2 and the onset of PD (P=0.08). A significant association was seen between caffeine intake and the onset of PD (P=2.01x10(-5)), with the odds ratio for moderate and high drinkers at 0.71 [95% confidence interval (CI): 0.50-1.00] and 0.47 (95% CI: 0.34-0.65), respectively against the low drinkers. Multivariate analysis revealed no evidence of any interaction effects of caffeine with CYP1A2 (P=0.956). CONCLUSION: The association between caffeine intake and risk of PD was similarly observed in both fast and slow caffeine metabolizers, supporting experimental evidence in animal models that both caffeine and its major metabolite, paraxanthine, are neuroprotective. SN - 1744-6872 UR - https://www.unboundmedicine.com/medline/citation/18075470/Association_between_caffeine_intake_and_risk_of_Parkinson's_disease_among_fast_and_slow_metabolizers_ L2 - https://doi.org/10.1097/FPC.0b013e3282f09265 DB - PRIME DP - Unbound Medicine ER -